Skip to main content
Erschienen in: Clinical and Translational Oncology 11/2017

29.05.2017 | Research Article

Improving efficacy and efficiency through the implementation of a new organisational model in a Radiation Oncology Department

verfasst von: Y. Lupiañez-Perez, J. Gomez-Millan, M. Lobato, P. Pedrosa, I. Lupiañez-Perez, J. A. Medina

Erschienen in: Clinical and Translational Oncology | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

To evaluate a new organisational model, “process management” (PM), implemented in the Hospital Universitario Virgen de la Victoria (HUVV) compared with traditional models used in other Radiation Oncology Departments (RODs), in terms of efficacy and efficiency.

Methods

The study period ranged from September 2011 to August 2012. Efficacy was assessed, comparing the number of patients attended in first consultation and treated per month, average waiting time from referral to first visit and average waiting time from first visit to treatment. Data were collected from two public hospitals in Andalusia: the HUVV and another Public Hospital in Andalusia (PHA1). Efficiency was assessed comparing the costs per patient attended in first visit and treated at HUVV in 2012 compared with those of a second Public Hospital in Andalusia (PHA2) for 2008. The number of sessions saved using hypofractionation versus classical schemes during the year 2012 in HUVV was estimated, and the money saved was calculated.

Results

In the efficacy analysis, we found significant differences in the average waiting time for first visit, start of treatment, and the number of patients seen and treated annually. After calculating the total cost generated in the ROD, the efficiency analysis showed a lower cost per patient attended in first visit (EUR 599.17) and per patient treated (EUR 783.50), with a saving of 6035 sessions using hypofractionated schemes.

Conclusions

Process management in an ROD reduces time, both to first medical visit and to treatment initiation, allowing an optimisation of linear accelerator (LINAC) capacity.
Literatur
1.
Zurück zum Zitat Rosenblatt E, Izewska J, Anacak Y, Pynda Y, Scalliet P, Boniol M, et al. RT capacity in European countries: an analysis of the Directory of RT Centres (DIRAC) database. Lancet Oncol. 2013;14(2):e79–86.CrossRefPubMed Rosenblatt E, Izewska J, Anacak Y, Pynda Y, Scalliet P, Boniol M, et al. RT capacity in European countries: an analysis of the Directory of RT Centres (DIRAC) database. Lancet Oncol. 2013;14(2):e79–86.CrossRefPubMed
2.
Zurück zum Zitat Downing A, Gilthorpe MS, Dodwell D, Lawrence G, Forman D. Waiting times for RT after breast-conserving surgery and the association with survival: a path analysis. Clin Oncol (R Coll Radiol). 2011;23(7):442–8.CrossRef Downing A, Gilthorpe MS, Dodwell D, Lawrence G, Forman D. Waiting times for RT after breast-conserving surgery and the association with survival: a path analysis. Clin Oncol (R Coll Radiol). 2011;23(7):442–8.CrossRef
3.
Zurück zum Zitat Kim K, Chie EK, Han W, Noh D-Y, Ha SW. Impact of delayed RT on local control in node-negative breast cancer patients treated with breast-conserving surgery and adjuvant RT without chemotherapy. Tumori. 2011;97(3):341–4.PubMed Kim K, Chie EK, Han W, Noh D-Y, Ha SW. Impact of delayed RT on local control in node-negative breast cancer patients treated with breast-conserving surgery and adjuvant RT without chemotherapy. Tumori. 2011;97(3):341–4.PubMed
4.
Zurück zum Zitat Wyatt RM, Jones BJ, Dale RG. RT treatment delays and their influence on tumour control achieved by various fractionation schedules. Br J Radiol. 2008;81(967):549–63.CrossRefPubMed Wyatt RM, Jones BJ, Dale RG. RT treatment delays and their influence on tumour control achieved by various fractionation schedules. Br J Radiol. 2008;81(967):549–63.CrossRefPubMed
5.
Zurück zum Zitat Lyhne NM, Christensen A, Alanin MC, Bruun MT, Jung TH, Bruhn MA, et al. Waiting times for diagnosis and treatment of head and neck cancer in Denmark in 2010 compared to 1992 and 2002. Eur J Cancer. 2013;49(7):1627–33.CrossRefPubMed Lyhne NM, Christensen A, Alanin MC, Bruun MT, Jung TH, Bruhn MA, et al. Waiting times for diagnosis and treatment of head and neck cancer in Denmark in 2010 compared to 1992 and 2002. Eur J Cancer. 2013;49(7):1627–33.CrossRefPubMed
6.
Zurück zum Zitat Chen CP, Weinberg VK, Jahan TM, Jablons DM, Yom SS. Implications of delayed initiation of RT: accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancer. J Thorac Oncol. 2011;6(11):1857–64.CrossRefPubMed Chen CP, Weinberg VK, Jahan TM, Jablons DM, Yom SS. Implications of delayed initiation of RT: accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancer. J Thorac Oncol. 2011;6(11):1857–64.CrossRefPubMed
7.
Zurück zum Zitat Rivera C, Mathiaux J, Haaser T, Becqueret H, Jougon J, Trouette R, et al. Delays in the diagnosis and treatment of lung cancer for patients treated with radiation therapy. Bull Cancer. 2012;99(12):1117–22.PubMed Rivera C, Mathiaux J, Haaser T, Becqueret H, Jougon J, Trouette R, et al. Delays in the diagnosis and treatment of lung cancer for patients treated with radiation therapy. Bull Cancer. 2012;99(12):1117–22.PubMed
8.
Zurück zum Zitat Paul C, Carey M, Anderson A, Mackenzie L, Sanson-Fisher R, Courtney R, et al. Cancer patients’ concerns regarding access to cancer care: perceived impact of waiting times along the diagnosis and treatment journey. Eur J Cancer Care Engl. 2012;21(3):321–9.CrossRefPubMedPubMedCentral Paul C, Carey M, Anderson A, Mackenzie L, Sanson-Fisher R, Courtney R, et al. Cancer patients’ concerns regarding access to cancer care: perceived impact of waiting times along the diagnosis and treatment journey. Eur J Cancer Care Engl. 2012;21(3):321–9.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Herruzo I, Romero J, Palacios A, Mañas A, Samper P, Bayo E. Libro Blanco SEOR XXI. Análisis de la situación y estrategias de futuro. In Libro blanco de SEOR. 1st ed. Editores Medicos SA (EDIMSA). 2010;53–95. Herruzo I, Romero J, Palacios A, Mañas A, Samper P, Bayo E. Libro Blanco SEOR XXI. Análisis de la situación y estrategias de futuro. In Libro blanco de SEOR. 1st ed. Editores Medicos SA (EDIMSA). 2010;53–95.
10.
Zurück zum Zitat Peiró M, Barrubés J. New context and old challenges in the healthcare system. Rev Esp Cardiol. 2012;65(7):651–5.CrossRefPubMed Peiró M, Barrubés J. New context and old challenges in the healthcare system. Rev Esp Cardiol. 2012;65(7):651–5.CrossRefPubMed
11.
Zurück zum Zitat Mannino M, Yarnold JR. Shorter fractionation schedules in breast cancer RT: clinical and economic implications. Eur J Cancer. 2009;45(5):730–1.CrossRefPubMed Mannino M, Yarnold JR. Shorter fractionation schedules in breast cancer RT: clinical and economic implications. Eur J Cancer. 2009;45(5):730–1.CrossRefPubMed
12.
Zurück zum Zitat Ko EC, Forsythe K, Buckstein M, Kao J, Rosenstein B. Radiobiological rationale and clinical implications of hypofractionated radiation therapy. Cancer Radiother. 2011;15(3):221–9.CrossRefPubMed Ko EC, Forsythe K, Buckstein M, Kao J, Rosenstein B. Radiobiological rationale and clinical implications of hypofractionated radiation therapy. Cancer Radiother. 2011;15(3):221–9.CrossRefPubMed
13.
Zurück zum Zitat Montero A, Sanz X, Herranz R, Cabrera D, Arenas M, Bayo E. Accelerated hypofractionated breast radiotherapy: FAQs (frequently asked questions). Breast. 2014;23(4):299–309.CrossRefPubMed Montero A, Sanz X, Herranz R, Cabrera D, Arenas M, Bayo E. Accelerated hypofractionated breast radiotherapy: FAQs (frequently asked questions). Breast. 2014;23(4):299–309.CrossRefPubMed
14.
Zurück zum Zitat Prades J, Algara M, Espinas JA, Farrus B, Arenas M, Reyes V. Understanding variations in the use of hypofractionated radiotherapy and its specific indications for breast cancer: a mixed-methods study. Radiother Oncol. 2017;123(1):22–8.CrossRefPubMed Prades J, Algara M, Espinas JA, Farrus B, Arenas M, Reyes V. Understanding variations in the use of hypofractionated radiotherapy and its specific indications for breast cancer: a mixed-methods study. Radiother Oncol. 2017;123(1):22–8.CrossRefPubMed
15.
Zurück zum Zitat Pennings PS, Goodman JM. Toward a workable framework. In: Pennings PS, Goodman JM, editors. New perspectives on organizational effetiveness. San Francisco: Jossey-Bass; 1977. p. 146–84. Pennings PS, Goodman JM. Toward a workable framework. In: Pennings PS, Goodman JM, editors. New perspectives on organizational effetiveness. San Francisco: Jossey-Bass; 1977. p. 146–84.
16.
Zurück zum Zitat Calzas A, García I, Goicoetxea J, Ruir FJ, Moyano A, Pablos A, Perez JM, Rosado M. Programa de Control de Gestión Hospitalaria (COANh). Sevilla: Servicio Andaluz de Salud. Consejería de Salud; 1997. Calzas A, García I, Goicoetxea J, Ruir FJ, Moyano A, Pablos A, Perez JM, Rosado M. Programa de Control de Gestión Hospitalaria (COANh). Sevilla: Servicio Andaluz de Salud. Consejería de Salud; 1997.
17.
Zurück zum Zitat Ballesta AM, Bedini JL, Gaya J, Mas E, Pascual C, Raventós J. Aproximación al cálculo del coste estándar por determinación: unidades relativas de valor (URV). Todo Hosp. 1994;107:43–50. Ballesta AM, Bedini JL, Gaya J, Mas E, Pascual C, Raventós J. Aproximación al cálculo del coste estándar por determinación: unidades relativas de valor (URV). Todo Hosp. 1994;107:43–50.
18.
Zurück zum Zitat Porceddu SV, Rosser B, Burmeister BH, Jones M, Hickey B, Baumann K, et al. Hypofractionated radiotherapy for the palliation of advanced head and neck cancer in patients unsuitable for curative treatment-"Hypo Trial". Radiother Oncol. 2007;85(3):456–62.CrossRefPubMed Porceddu SV, Rosser B, Burmeister BH, Jones M, Hickey B, Baumann K, et al. Hypofractionated radiotherapy for the palliation of advanced head and neck cancer in patients unsuitable for curative treatment-"Hypo Trial". Radiother Oncol. 2007;85(3):456–62.CrossRefPubMed
19.
Zurück zum Zitat Rodrigues G, Videtic GMM, Sur R, Bezjak A, Bradley J, Hahn CA, et al. Palliative thoracic RT in lung cancer: an American Society for Radiation Oncology evidence-based clinical practice guideline. Pract Radiat Oncol. 2011;1(2):60–71.CrossRefPubMedPubMedCentral Rodrigues G, Videtic GMM, Sur R, Bezjak A, Bradley J, Hahn CA, et al. Palliative thoracic RT in lung cancer: an American Society for Radiation Oncology evidence-based clinical practice guideline. Pract Radiat Oncol. 2011;1(2):60–71.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, et al. The UK Standardisation of Breast RT (START) Trial A of RT hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008;9(4):331–41.CrossRefPubMed Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, et al. The UK Standardisation of Breast RT (START) Trial A of RT hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008;9(4):331–41.CrossRefPubMed
21.
Zurück zum Zitat Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010;78(1):11–8.CrossRefPubMed Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010;78(1):11–8.CrossRefPubMed
22.
Zurück zum Zitat Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M, et al. Long-term results of a randomized trial comparing preoperative short-course RT with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93:1215–23.CrossRefPubMed Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M, et al. Long-term results of a randomized trial comparing preoperative short-course RT with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93:1215–23.CrossRefPubMed
23.
Zurück zum Zitat Kaasa S, Brenne E, Lund JA, Fayers P, Falkmer U, Holmberg M, et al. Prospective randomised multicenter trial on single fraction RT (8 Gy × 1) versus multiple fractions (3 Gy × 10) in the treatment of painful bone metastases. Radiother Oncol. 2006;79(3):278–84.CrossRefPubMed Kaasa S, Brenne E, Lund JA, Fayers P, Falkmer U, Holmberg M, et al. Prospective randomised multicenter trial on single fraction RT (8 Gy × 1) versus multiple fractions (3 Gy × 10) in the treatment of painful bone metastases. Radiother Oncol. 2006;79(3):278–84.CrossRefPubMed
24.
Zurück zum Zitat Consejería de Salud. Plan Integral de Oncología 2007-2012. Sevilla: Junta de Andalucía, Consejería de Salud; 2007. Consejería de Salud. Plan Integral de Oncología 2007-2012. Sevilla: Junta de Andalucía, Consejería de Salud; 2007.
25.
Zurück zum Zitat Govijarm R. El desorden sanitario tiene cura. Desde la seguridad del paciente hasta la sostenibilidad del sistema sanitario con la gestión por procesos. 1st ed. Barcelona: Marge Medica Books 2009; 29–53. Govijarm R. El desorden sanitario tiene cura. Desde la seguridad del paciente hasta la sostenibilidad del sistema sanitario con la gestión por procesos. 1st ed. Barcelona: Marge Medica Books 2009; 29–53.
26.
Zurück zum Zitat Armstrong EG, Barsion SJ. Creating “innovator’s DNA” in health care education. Acad Med. 2013;88(3):343–8.CrossRefPubMed Armstrong EG, Barsion SJ. Creating “innovator’s DNA” in health care education. Acad Med. 2013;88(3):343–8.CrossRefPubMed
27.
Zurück zum Zitat Scoccianti S, Agresti B, Simontacchi G, Detti B, Cipressi S, Iannalfi A, et al. From a waiting list to a priority list: a computerized model for an easy-to-manage and automatically updated priority list in the booking of patients waiting for RT. Tumori. 2012;98(6):728–35.PubMed Scoccianti S, Agresti B, Simontacchi G, Detti B, Cipressi S, Iannalfi A, et al. From a waiting list to a priority list: a computerized model for an easy-to-manage and automatically updated priority list in the booking of patients waiting for RT. Tumori. 2012;98(6):728–35.PubMed
28.
Zurück zum Zitat Palacios Eito A, Espinosa Calvo M, Mañas Rueda A, de Las Heras M. Radiation oncology: future needs and equipment. Current situation in Spain. Clin Transl Oncol. 2008;10(8):478–85.CrossRefPubMed Palacios Eito A, Espinosa Calvo M, Mañas Rueda A, de Las Heras M. Radiation oncology: future needs and equipment. Current situation in Spain. Clin Transl Oncol. 2008;10(8):478–85.CrossRefPubMed
29.
Zurück zum Zitat Esco R, Palacios A, Pardo J, Biete A, Carceller JA, Veiras C, et al. Infrastructure of RT in Spain: a minimal standard of RT resources. Int J Radiat Oncol Biol Phys. 2003;56(2):319–27.CrossRefPubMed Esco R, Palacios A, Pardo J, Biete A, Carceller JA, Veiras C, et al. Infrastructure of RT in Spain: a minimal standard of RT resources. Int J Radiat Oncol Biol Phys. 2003;56(2):319–27.CrossRefPubMed
30.
Zurück zum Zitat Slotman BJ, Vos PH. Planning of RT capacity and productivity. Radiother Oncol Febrero de. 2013;106(2):266–70.CrossRef Slotman BJ, Vos PH. Planning of RT capacity and productivity. Radiother Oncol Febrero de. 2013;106(2):266–70.CrossRef
31.
Zurück zum Zitat The START Trialists’ Group. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371:1098–107.CrossRefPubMedCentral The START Trialists’ Group. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371:1098–107.CrossRefPubMedCentral
Metadaten
Titel
Improving efficacy and efficiency through the implementation of a new organisational model in a Radiation Oncology Department
verfasst von
Y. Lupiañez-Perez
J. Gomez-Millan
M. Lobato
P. Pedrosa
I. Lupiañez-Perez
J. A. Medina
Publikationsdatum
29.05.2017
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 11/2017
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1678-2

Weitere Artikel der Ausgabe 11/2017

Clinical and Translational Oncology 11/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.